- Home
- SAMG vs DMAC Comparison
SAMG vs DMAC Comparison
Compare SAMG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAMG
- DMAC
- Stock Information
- Founded
- SAMG 2002
- DMAC 2000
- Country
- SAMG United States
- DMAC United States
- Employees
- SAMG N/A
- DMAC N/A
- Industry
- SAMG Investment Managers
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SAMG Finance
- DMAC Health Care
- Exchange
- SAMG Nasdaq
- DMAC Nasdaq
- Market Cap
- SAMG 171.2M
- DMAC 172.7M
- IPO Year
- SAMG 2013
- DMAC N/A
- Fundamental
- Price
- SAMG $18.29
- DMAC $4.18
- Analyst Decision
- SAMG
- DMAC Strong Buy
- Analyst Count
- SAMG 0
- DMAC 3
- Target Price
- SAMG N/A
- DMAC $7.00
- AVG Volume (30 Days)
- SAMG 24.9K
- DMAC 46.2K
- Earning Date
- SAMG 10-31-2024
- DMAC 11-13-2024
- Dividend Yield
- SAMG 4.40%
- DMAC N/A
- EPS Growth
- SAMG N/A
- DMAC N/A
- EPS
- SAMG 0.79
- DMAC N/A
- Revenue
- SAMG $120,231,000.00
- DMAC N/A
- Revenue This Year
- SAMG $7.10
- DMAC N/A
- Revenue Next Year
- SAMG $5.89
- DMAC N/A
- P/E Ratio
- SAMG $22.68
- DMAC N/A
- Revenue Growth
- SAMG 2.45
- DMAC N/A
- 52 Week Low
- SAMG $13.93
- DMAC $2.14
- 52 Week High
- SAMG $18.77
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- SAMG 58.97
- DMAC 48.23
- Support Level
- SAMG $18.10
- DMAC $3.96
- Resistance Level
- SAMG $18.77
- DMAC $4.21
- Average True Range (ATR)
- SAMG 0.44
- DMAC 0.18
- MACD
- SAMG 0.02
- DMAC -0.02
- Stochastic Oscillator
- SAMG 80.95
- DMAC 50.00
About SAMG Silvercrest Asset Management Group Inc.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.